Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5691933 | 0.85 | LOXL2 (0.47) | NPC1RAB9AMETCYP3A4TSHR | |
| SCHEMBL2387794 | 0.82 | NPC1 (0.57) | NPC1RAB9AMETALDH1A1SMN1; SMN2 | |
| SCHEMBL86139 | 0.82 | ALDH1A1 (0.47) | NPC1RAB9AMETCYP3A4TSHR | |
| SCHEMBL3235233 | 0.82 | NPC1 (0.57) | NPC1RAB9AGFERMETCYP3A4 | |
| SCHEMBL8652676 | 0.82 | LMNA (0.45) | NPC1RAB9ATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL4242570 | 0.82 | ALDH1A1 (0.62) | NPC1RAB9AMETCYP3A4TSHR | |
| SCHEMBL27578680 | 0.82 | NPC1 (0.50) | NPC1RAB9AGFERMETCYP3A4 | |
| SCHEMBL10053298 | 0.81 | L3MBTL1 (0.44) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL1067152 | 0.81 | SIRT2 (0.47) | TSHRALDH1A1SMN1; SMN2L3MBTL1MAOA | |
| SCHEMBL86418 | 0.81 | KMT2A (0.55) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383893-A1 | Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof | HAIHE BIOPHARMA CO., LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| EP-4400493-A1 | HYDROXAMIC ACID COMPOUND HAVING ENPP1 INHIBITORY ACTIVITY AND USE THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-20230049294-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-02-16 | — | — | US | disclosed |
| EP-1887008-B1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-04-21 | — | — | EP | disclosed |
| CN-112334319-A | Thermosensitive recording material | 王子控股株式会社 | 2021-02-05 | — | — | CN | disclosed |
| WO-2017008708-A1 | METHOD FOR PREPARING INDAZOLE COMPOUND AND USE THEREOF | 中国科学院上海药物研究所 | 2017-01-19 | — | — | WO | disclosed |
| US-9249308-B2 | Compound having bisazo dye skeleton, pigment composition containing the same, pigment dispersion, ink, and color filter resist composition | CANON KABUSHIKI KAISHA (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20140326931-A1 | NOVEL COMPOUND HAVING BISAZO DYE SKELETON, PIGMENT COMPOSITION CONTAINING THE SAME, PIGMENT DISPERSION, INK, AND COLOR FILTER RESIST COMPOSITION | CANON KABUSHIKI KAISHA (JP) | 2014-11-06 | — | — | US | disclosed |
| CN-101903375-B | Carboxyl- or hydroxyl-substituted benzimidazole derivatives | HOFFMANN LA ROCHE | 2014-05-21 | — | — | CN | disclosed |
| CN-103814016-A | Compositions and methods for producing pyrimidine and pyridine compounds having BTK inhibitory activity | MERCK PATENT GMBH | 2014-05-21 | — | — | CN | disclosed |
| CN-101583597-A | Sulfonamide derivatives as liver carnitine palmitoyl transferase (L-CPT1) | HOFFMANN LA ROCHE (CH) | 2009-11-18 | — | — | CN | disclosed |
| EP-1887008-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-02-13 | — | — | EP | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7208598-B2 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | AVENTIS PHARMA (FR) | 2007-04-24 | — | — | US | disclosed |
| CN-1914173-A | Quinolines useful in treating cardiovascular disease | WYETH CORP (US) | 2007-02-14 | — | — | CN | disclosed |
| US-7122669-B1 | Purine derivatives, preparation method and pharmaceutical compositions containing same | HOECHST MARION ROUSSEL (FR) | 2006-10-17 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20050187228-A1 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. | 2005-08-25 | — | — | US | disclosed |
| US-4000274-A | PHARMACEUTICAL COMPOSITIONS CONTAINING AN N-ARYL-N'-(PHENYL-OR-PHENOXY-ALKYL)-PIPERAZINE AND METHOD OF USE | BOEHRINGER INGELHEIM GMBH (DT) | 1976-12-28 | — | — | US | disclosed |
| US-3941789-A | CNS DEPRESSANT, ADRENOLYTIC, ANTIPHLOGISTIC, ANALGESIC, ANTIHISTAMINE, ANTICHOLESTEROL | BOEHRINGER INGELHEIM GMBH (DT) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383893-A1 | Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof | ENPP1, ENPP2, ENPP3 | NPC1 868/4885RAB9A 962/4885GFER 4613/4885 |
| US-20050187228-A1 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | CDK6, CDK1, CDK2 | NPC1 3546/4885RAB9A 2279/4885GFER 4342/4885 |
| US-20230049294-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | NUDT1, PNP, ITPA | NPC1 995/4885RAB9A 1269/4885GFER 3900/4885 |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | NPC1 1085/4885RAB9A 1813/4885GFER 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.